A Chat with Joe Jonas

Global superstar, musician, and actor shares how EVO changed his life.

Jj homepage image v10 resized

Joe Jonas’ struggle with bad vision

Joe Jonas had myopia since childhood, which is also known as nearsightedness or the need for distance vision correction. Myopia is the most common vision disorder in the world and its prevalence is rapidly growing.

Joe dreamed of a day where he could live life uninhibited by his nearsightedness. Jonas had the EVO procedure which involved his doctor adding a small, flexible lens in both eyes to correct his distance vision and is now free from the daily hassles of contact lenses and eyeglasses.

EVO provides excellent sharp, clear vision day and night, does not induce dry eye syndrome and preserves the cornea. If desired, EVO lenses are also removable by a doctor for added peace of mind.

Joe Jonas testimonial page video thumbnialv2

Why Joe Jonas chose the EVO ICL lens (EVO)

After speaking with my doctor about this advanced new technology, I chose EVO as I felt like it was finally time to upgrade my vision and change how I could see the world. It was a seamless, easy procedure for me that quickly gave me sharp, clear vision day or night without inducing dry eye syndrome. The results are life changing for me and with EVO, I now can simply wake up and go about my day.” – Joe Jonas

Jj image section break testimonial page

Ready to Discover Visual Freedom With EVO ICL? Find a Doctor Today

Important Safety Information

The EVO Visian ICL & EVO Visian TICL is designed for the correction/reduction of myopia in adults ranging from -0.5 D to -20.0 D with less than or equal to 6.0 D of astigmatism at the spectacle plane. The Canada EVO Visian models have a spherical power range of -3.0 D to -18.0 D and cylinder power range of 1.0 D to 6.0 D. The Canada EVO+ Visian ICL models have a spherical power range of -3.0 D to -14.0 D and cylinder power range of 1.0 D to 6.0 D. The hyperopic EVO Visian ICL’s are available in powers ranging from +3.0 to +10.0 diopters for the correction/reduction of hyperopia. The ICLs are indicated for patients who are 21 to 60 years of age. In order to be sure that your surgeon will use a EVO Visian ICL with the most adequate power for your eye, your nearsightedness, farsightedness and astigmatism should be stable for at least a year before undergoing eye surgery. EVO Visian ICL surgery may improve your vision without eyeglasses or contact lenses. EVO Visian ICL surgery does not eliminate the need for reading glasses, even if you have never worn them before. EVO Visian ICL represents an alternative to other refractive surgeries including, laser assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), incisional surgeries, or other means to correct your vision such as contact lenses and eye glasses. Implantation of an EVO Visian ICL is a surgical procedure, and as such, carries potentially serious risks. The following represent potential complications/adverse reactions reported in conjunction with refractive surgery in general: additional surgeries, cataract formation, loss of best corrected vision, raised pressure inside the eye, loss of cells on the innermost surface of the cornea, conjunctival irritation, acute corneal swelling, persistent corneal swelling, endophthalmitis (total eye infection), significant glare and/or halos around lights, hyphaema (blood in the eye), hypopyon (pus in the eye), eye infection, EVO Visian ICL dislocation, macular oedema, non-reactive pupil, pupillary block glaucoma, severe inflammation of the eye, iritis, uveitis, vitreous loss and corneal transplant. Before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery.

References

References

1. Patient Survey, STAAR Surgical ICL Data Registry, 2018

2. Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46. Patient Survey, STAAR Surgical ICL Data Registry, 2018

3. Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.

4. Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.

5a. Lee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.

5b. Parkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.

*American Refractive Surgery Council